522
Views
3
CrossRef citations to date
0
Altmetric
Letters to the Editor

Clinical characteristics and outcomes of duodenal-type follicular lymphoma

, , , , , , , , , , , , & show all
Pages 3266-3268 | Received 05 Feb 2020, Accepted 04 Jul 2020, Published online: 22 Jul 2020
 

Disclosure statement

TM received research funding from MSD, Novartis Pharma, LSI Medience, Medical & Biological Laboratories, and Asahi Kasei Corporation, and personal fees from Pfizer Inc., MSD, Janssen Pharma, Sumitomo Dainippon Pharma, Novartis Pharma, Kyowa Kirin, Chugai Pharmaceutical, Shionogi & Co., Japan Blood Products Organization, Takeda Pharmaceutical, Ono Pharmaceutical, Shire, Eisai, and Astellas Pharma; TK received personal fees from Chugai Pharmaceutical, Eisai, Kyowa Kirin, Janssen Pharma, Takeda Pharmaceutical, and Bristol-Myers Squibb; JK received personal fees from Astellas Pharma, Otsuka Pharmaceutical, Janssen Pharma, Pfizer, Takeda Pharmaceutical, and JCR Pharmaceuticals; TS received personal fees from Janssen Pharma, Kyowa Kirin, Takeda Pharmaceutical, Celgene, Ono Pharmaceutical, and Eisai; SO received research funding from Chugai Pharmaceutical, Sumitomo Dainippon Pharma, Pfizer, Teijin Pharma, Novartis Pharma, Bristol-Myers Squibb, Mochida Pharmaceutical, JCR Pharmaceuticals, Toyama Chemical, Takeda Pharmaceutical, Daiichi Sankyo, Shionogi & Co., Sanofi, Kyowa Kirin, Ono Pharmaceutical, Otsuka Pharmaceutical, Eisai, Asahi Kasei Corporation, and Japan Blood Products Organization, and personal fees from Chugai Pharmaceutical, Eisai, Kyowa Kirin, Janssen Pharma, and Takeda Pharmaceutical.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.